Hostname: page-component-74656f9884-rdgjk Total loading time: 0 Render date: 2026-11-09T00:15:50.916Z Has data issue: false hasContentIssue false

Expression of Plasmodium falciparum 3D7 STEVOR proteins for evaluation of antibody responses following malaria infections in naïve infants

Published online by Cambridge University Press:  12 October 2007

N. SCHREIBER
Affiliation:
Infectious Disease Epidemiology Group, Bernhard-Nocht Institute for Tropical Medicine, Bernhard-Nocht-Strasse 74, 20359 Hamburg, Germany
A. KHATTAB
Affiliation:
Department of Molecular Medicine, Bernhard-Nocht Institute for Tropical Medicine, Bernhard-Nocht-Strasse 74, 20359 Hamburg, Germany
M. PETTER
Affiliation:
Department of Molecular Medicine, Bernhard-Nocht Institute for Tropical Medicine, Bernhard-Nocht-Strasse 74, 20359 Hamburg, Germany
F. MARKS
Affiliation:
Infectious Disease Epidemiology Group, Bernhard-Nocht Institute for Tropical Medicine, Bernhard-Nocht-Strasse 74, 20359 Hamburg, Germany International Vaccine Institute, Kwanak PO Box 14, Seoul 151-600, South Korea
S. ADJEI
Affiliation:
Kumasi Centre for Collaborative Research in Tropical Medicine, KNUST University Post Office, Kumasi, Ghana
R. KOBBE
Affiliation:
Infectious Disease Epidemiology Group, Bernhard-Nocht Institute for Tropical Medicine, Bernhard-Nocht-Strasse 74, 20359 Hamburg, Germany
J. MAY
Affiliation:
Infectious Disease Epidemiology Group, Bernhard-Nocht Institute for Tropical Medicine, Bernhard-Nocht-Strasse 74, 20359 Hamburg, Germany
M.-Q. KLINKERT*
Affiliation:
Department of Molecular Medicine, Bernhard-Nocht Institute for Tropical Medicine, Bernhard-Nocht-Strasse 74, 20359 Hamburg, Germany
*
*Corresponding author: Bernhard Nocht Institute for Tropical Medicine, Bernhard-Nocht-Strasse 74, 20359 Hamburg, Germany. Tel: +49 40 42818301. Fax: +49 40 42818400. E-mail: mo.klinkert@bni-hamburg.de
Rights & Permissions [Opens in a new window]

Summary

Clinical immunity to Plasmodium falciparum malaria develops after repeated exposure to the parasite. At least 2 P. falciparum variant antigens encoded by multicopy gene families (var and rif) are targets of this adaptive antibody-mediated immunity. A third multigene family of variant antigens comprises the stevor genes. Here, 4 different stevor sequences were selected for cloning and expression in Escherichia coli and His6–tagged fusion proteins were used for assessing the development of immunity. In a cross-sectional analysis of clinically immune adults living in a malaria endemic area in Ghana, high levels of anti-STEVOR IgG antibody titres were determined in ELISA. A cross-sectional study of 90 nine-month-old Ghanaian infants using 1 recombinant STEVOR showed that the antibody responses correlated positively with the number of parasitaemia episodes. In a longitudinal investigation of 17 immunologically naïve 9-month-old infants, 3 different patterns of anti-STEVOR antibody responses could be distinguished (high, transient and low). Children with high anti-STEVOR-antibody levels exhibited an elevated risk for developing parasitaemia episodes. Overall, a protective effect could not be attributed to antibodies against the STEVOR proteins chosen for the study presented here.

Information

Type
Research Article
Copyright
Copyright © Cambridge University Press 2007
Figure 0

Fig. 1. (A) STEVOR protein organization. STEVOR proteins comprise a signal peptide (SP) encoded by the first exon, followed by a semi-conserved (SC) region and a hyper-variable (HV) region. The latter is flanked by 2 predicted transmembrane (TM) domains (Cheng et al.1998). Following the second TM is a short C-terminal region (CT). Expressed regions are delineated by the arrows. The map is not drawn to scale. (B) Protein sequence alignment of STEVOR variants. Sequence homologies are highlighted in blue (for 100% identity), in red (75% identity) and in green (50% identity). Amino acids on which primers were constructed are framed. The HV region is marked with arrowheads. (C) Phylogenetic tree of 3D7 STEVOR proteins. Two major subgroups termed A and B could be classified. STEVOR variants used in this study are highlighted as black boxes. Bootstrap values are indicated in the tree.

Figure 1

Fig. 2. Western blot analysis. Polyclonal mouse anti-STEVOR-antibodies raised against the 4 different variants (shown for MAL13P1.7) recognize different native STEVOR proteins in the enriched membrane fractions of different laboratory-adapted field isolates (Gb337, VIP43, Chc03) as well as the Plasmodium falciparum reference strain 3D7.

Figure 2

Fig. 3. Frequency of recognition of recombinant proteins by human sera. The percentage of sera containing antibodies to 0, 1, 2, 3 or 4 STEVOR variants was determined. Positive test samples are those with an RU above the cut-off value, calculated as the mean of RU±3 s.d. of the European controls.

Figure 3

Fig. 4. Dot plots of anti-STEVOR-IgG responses. IgG levels against different recombinant STEVOR variants and against a Plasmodium falciparum lysate were determined in 195 African adults by ELISA and shown in a pairwise comparison. Spearman's rank correlation coefficient values (rho) are indicated in each box.

Figure 4

Fig. 5. Comparison of median (interquartile range) antibody levels with parasitaemia episodes. IgG levels against total Plasmodium falciparum antigens and recombinant STEVOR protein encoded by the PFC0025c gene were determined by ELISA. The participants were divided according to their accumulated number of parasitaemia episodes during their 3rd to 9th months of life. The 3 groups were those with no detectable parasitaemia episodes (n=30), one (n=22) and two or more (n=38). P values were calculated using the Mann-Whitney test.

Figure 5

Fig. 6. Antibody profiles observed during follow-up. Plasma samples were taken every 3 months and analysed for anti-STEVOR- (solid line) and anti-Plasmodium falciparum- (dotted line) antibodies by ELISA, expressed as RU (relative units) based on measured OD values. Vertical solid lines illustrate the time-points when the patients become parasitaemic, the height of the line representing the parasite density (calculated as the logarithm of parasitaemia).

Figure 6

Fig. 7. Scheme of the longitudinal study. Children were monitored on a monthly basis (black dots) starting at the age of 3 months through to 24 months. Blood samples were taken at 3-monthly intervals (indicated by vertical lines) for IgG determinations against STEVOR and Plasmodium falciparum lysate. The scheme further distinguishes (i) the assessment of the occurrence and outcome of parasitaemia (Pst), detected 1 month prior to IgG determination on anti-STEVOR antibody levels (open horizontal arrow above the time-line) from (ii) the assessment of anti-STEVOR antibody levels on Pst (solid horizontal arrow below the time-line).

Figure 7

Table 1. Statistical analysis of parasite and IgG determinations(Anti-STEVOR IgG responses were measured by ELISA in 17 children every 3 months from 9 to 24 months of age. A total of 85 events were theoretically available for analysis (5 visits in 17 children). This number (n) was accordingly reduced if follow-up visits were missing, so that 84 events were available for the first analysis (effect of parasitaemia on IgG at months 12, 15, 18, 21 and 24) and 81 for the second analysis (effect of IgG at months 9, 12, 15, 18 and 21 on parasitaemia). There was a period of 1 month between parasite determination and IgG determination or vice versa. P values were calculated using the Mann-Whitney test.)